Share
News
-
19 September 2008 /Product information
National meeting about the Pharmaceutical Forum held 12 September 2008
On 12 September 2008, the Danish Medicines Agency hosted a national meeting about the Pharmaceutical Forum held by the Danish Ministry of Health and Prevention and the Danish Medicines Agency.
-
12 September 2008 /Product information
Withdrawal of the asthma and lung medicine Oxis Turbohaler® with batch no. IA763-3
2care4 has, in cooperation with the Danish Medicines Agency, chosen to withdraw Oxis Turbohaler® with batch no. IA763-3 from Danish pharmacies. The company has chosen to do so because of the risk that packages in this batch may contain turbohalers with the wrong dose relative to the strength stated on the package.
-
27 August 2008 /Product information
Thalidomide Pharmion (thalidomide) on the Danish market as of 25 August 2008
Thalidomide Pharmion is authorised in the EU as first line treatment of multiple myeloma, which is a relatively rare cancer of the bone marrow. Thalidomide Pharmion must be given in combination with the medicines melphalan and prednisone.
-
11 August 2008 /Product information
Warning against the product Melanotan
The Danish Medicines Agency has been made aware of the product, Melanotan, which is sold via the internet. The product is marketed as a product that increases pigmentation, providing tanned skin and protection against the harmful rays of the sun, implying that it may prevent skin cancer. However, this effect has not been documented.
-
25 July 2008 /Product information
EMEA recommends restricting the use of oral moxifloxacin-containing medicines
The European Medicines Agency (EMEA) has reviewed the safety of moxifloxacin-containing medicines for oral use. The EMEA has concluded that these medicines should only be prescribed for the treatment of acute bacterial sinusitis, acute exacerbation of chronic bronchitis and community-acquired pneumonia when other antibiotics cannot be used or have failed.
-
25 July 2008 /Product information
EMEA recommends restricted use of oral norfloxacin-containing medicines in urinary infections
The European Medicines Agency has recommended restricting the use of oral norfloxacin-containing medicines in urinary infections.
-
25 July 2008 /Product information
No increased risk of developing cancer for patients having taken Viracept® contaminated with ethyl mesilate
Following a review of a number of toxicology studies, the European Medicines Agency (EMEA) has confirmed that there is no increased risk of development of cancer for patients who have taken contaminated Viracept® (Nelfinavir).
-
15 July 2008 /Product information
Warning against the product Viamax Energizer
The Danish Medicines Agency has become aware of the product Viamax Energizer, which is sold on the internet as a product providing energy. An analysis carried out by the Swedish Medical Products Agency has shown that the product contains the active substances levodopa and theophylline, which does not appear from the packages.
-
03 July 2008 /Product information
Recall of Nobligan® oral drops in Denmark
In cooperation with the Danish Medicines Agency, Grünenthal Aps has decided to recall all packs of Nobligan® oral drops, 100mg/ml (pack sizes of 10 ml and 96 ml) in Denmark.
-
04 June 2008 /Product information
EMEA recommends changes in the storage conditions for Neupro® (rotigotine)
The European Medicines Agency (EMEA) has recommended the immediate implementation of changes to the product information for Neupro® (rotigotine), from Schwarz Pharma Ltd., stating that it must be stored in a refrigerator (at a temperature of between 2ºC and 8ºC).
-
27 May 2008 /Product information
Danish Medicines Agency warns against the weight-loss product Therma Power
The Danish Medicines Agency strongly warns against Therma Power Red and similar products with the same content and characteristics. Therma Power Red contains ephedrine and is illegal in Denmark.
-
30 April 2008 /Product information
Warning against the product Wodibo
The Danish Medicines Agency has been made aware of the Chinese potency-enhancing product, Wodibo, which is sold via the internet. Wodibo is not a licensed medicinal product, and we therefore warn against using it.
-
17 April 2008 /Product information
Dexofan® is made prescription-only
Today, the Danish Medicines Agency passed a decision to clasify Dexofan® as a prescription-only medicine in dispensing group A on recommendation by the Licensing Committee.
-
03 April 2008 /Product information
Warning against vpxl N°1 Dietary Supplement for Men
The medicines authorities in Luxembourg have found a product that contains the active substance tadalafil, which did not appear from the packages. The product concerned is vpxl N°1 Dietary Supplement for Men, which is sold on the internet.
-
18 March 2008 /Product information
Warning about Power 1 Walnut
The Danish Medicines Agency has been made aware that the Health Sciences Authority in Singapore has confiscated large quantities of the illegal medicinal product Power 1 Walnut, which has been marketed as a potency-enhancing product containing only herbs.
-
22 February 2008 /Product information
Warning against the products Herb Vigour, China Vigour and Natural Vigour
The Danish Medicines Agency has been made aware that the products Herb Vigour, China Vigour and Natural Vigour are being sold on the Danish langauge version of www.eco-herbs.com.
-
30 January 2008 /Product information
The Danish Medicines Agency and the Danish Veterinary and Food Administration warn against the weight loss product Therma Power
The Danish Medicines Agency strongly warns against Therma Power and products with a similar content and characteristics. Therma Power contains ephedrine or synephrine and is illegal in Denmark.
